Biota Pharmaceuticals Inc

Type: Company
Name: Biota Pharmaceuticals Inc
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Reco Pharma Says Trial Study Not Seen Reaching Statistical Significance; FDA Removes Partial Clinical Hold on OncoMed's Ipafricept

Below is a look at some of the headlines for companies that made news in the healthcare sector on September 4, 2014.Recro Pharma, Inc. (Nasdaq: REPH) , a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment ... [Published BioMedReports - Sep 05 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Biota to Present Preclinical Data on RSV Compound BTA-C585 at ICAAC Meeting

ATLANTA, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. ( Nasdaq:BOTA ), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious ... [Published Franklin Credit Management Corporation - Sep 04 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Celator Pharmaceuticals names Michael Dougherty as board chair

The board of directors of Celator Pharmaceuticals (NasdaqCM:CPXX), a pharmaceutical company, reported on Wednesday the appointment of Michael R. Dougherty as its chairman. Dougherty, who has served as a member of the company's board since July 2013, replaces ... [Published Individual.com - Sep 04 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Celator(R) Pharmaceuticals Announces Appointment of Michael Dougherty as Chairman of the Board

EWING, N.J., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. ( Nasdaq:CPXX ), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the appointment of Michael R. Dougherty as Chairman of ... [Published WGNT - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Georgia’s Top 100 Public Companies

Analysis By Christy SimoA rising tide lifts all boats, and that’s no different in the economic realm. With the rebound in full swing, Georgia’s top companies continue to see growth both in financial earnings and number of employees.All together, this ... [Published Georgia Trend - Sep 02 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Alert: Biota Pharmaceuticals Inc (NASDAQ:BOTA) Faces Investor Investigation

San Diego, CA -- (SBWIRE) -- 08/19/2014 -- An investigation on behalf of investors of Biota Pharmaceuticals Inc (NASDAQ:BOTA) shares over potential securities laws violations by Biota Pharmaceuticals and certain of its directors and officers in connection ... [Published CEOWorld Magazine - Aug 19 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 1 reports

GenMark Diagnostics Appoints Dr. James Fox as Chairman of the Board

GenMark Diagnostics, Inc. ( Nasdaq:GNMK ), a leading provider ofautomated, multiplex molecular diagnostic testing systems, todayannounced the appointment of Dr. James Fox as Chairman of the Board. Dr.Fox is replacing Christopher Gleeson, who is retiring ... [Published TVNewsCheck - Aug 11 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 2 reports

TAXIS acquires novel antimicrobial drug candidates from Biota

TAXIS Pharmaceuticals, Inc. (the "Company") today announced the acquisition of a group of novel antimicrobial drug candidates from Biota Pharmaceuticals Inc. ("Biota") of Atlanta, GA. The acquisition will help expand the Company's ongoing research into ... [Published News-Medical.Net - Aug 11 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Biota Pharma announces positive results from phase 2 IGLOO trial of laninamivir octanoate

Biota Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced top-line data from a randomised, double-blind, ... [Published PharmaBiz - Aug 05 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota Pharmaceuticals, Inc.

SAN DIEGO--(BUSINESS WIRE)--BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota Pharmaceuticals, Inc ... [Published Business Wire Professional Services News - Aug 01 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

5 Stocks Under $10 Set to Soar

 DELAFIELD, Wis. (Stockpickr) -- There isn't a day that goes by on Wall Street when certain stocks trading for $10 a share or less don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline ... [Published The Street Latest - Jul 11 2014]
First reported Jun 04 2014 - Updated Jun 04 2014 - 1 reports

Research and Markets: Biota Pharmaceuticals, Inc. - Product Pipeline Review - 2014

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/965h3w/biota) has announced the addition of the "Biota Pharmaceuticals, Inc. - Product Pipeline Review - 2014" company profile to their offering. This report provides ... [Published Business Wire Health News - Jun 04 2014]

Quotes

...Wnt pathway programs, ipafricept and vantictumab, to be back underway soon," said Paul J Hastings, Chairman and Chief Executive Officer of OncoMed. "The Wnt pathway represents a highly promising target for disrupting cancer stem cell activity and inducing tumor differentiation. As we advance ipafricept and vantictumab through clinical studies in combination with standard of care, we expect to generate key data from these Phase 1b studies that will support a potential opt-in by our partner Bayer as well as late-stage clinical development."
The poster (F-1576) entitled "Preclinical Characterization of an Orally Bioavailable Fusion Inhibitor, BTA-C585, for the Treatment of RSV Infection" will be presented during the session "Miscellaneous Agents Including Antiviral and Antiparasitic Agents" on September 8, 2014 from 11:00 am - 1:00 pm...
...to his new role as Chairman, with extensive industry experience in strategy, finance and operations," said Scott Jackson, Chief Executive Officer. "We are also very grateful to Joe and recognize his many contributions to the company. We look forward to his continued guidance."
...spectrum of the emerging, drug-resistant pathogens that are a well-known and growing public healthhealth threat," said Gregory Mario, CEO of TAXIS. "When combined with our proprietary technology, the compounds appear to be effective against the two types of drug-resistant staph infections that most concern health care providers."

More Content

All (24) | News (12) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (10)
sort by: Date | Relevance
Biota Pharmaceuticals to Host Conference Call t... [Published GlobeNewswire: Advertising News - 19 hours ago]
Reco Pharma Says Trial Study Not Seen Reaching ... [Published BioMedReports - Sep 05 2014]
Biota to Present Preclinical Data on RSV Compou... [Published GlobeNewswire: Acquisitions News - Sep 04 2014]
Biota to Present Preclinical Data on RSV Compou... [Published Franklin Credit Management Corporation - Sep 04 2014]
Celator Pharmaceuticals names Michael Dougherty... [Published Individual.com - Sep 04 2014]
Celator(R) Pharmaceuticals Announces Appointmen... [Published WGNT - Sep 03 2014]
Georgia’s Top 100 Public Companies [Published Georgia Trend - Sep 02 2014]
Alert: Biota Pharmaceuticals Inc (NASDAQ:BOTA) ... [Published CEOWorld Magazine - Aug 19 2014]
GenMark Diagnostics Appoints Dr. James Fox as C... [Published TVNewsCheck - Aug 11 2014]
TAXIS acquires novel antimicrobial drug candida... [Published News-Medical.Net - Aug 11 2014]
TAXIS Pharmaceuticals Expands Research Portfolio [Published Newswise - Aug 11 2014]
Biota Pharma announces positive results from ph... [Published PharmaBiz - Aug 05 2014]
BIOTA ALERT: Shareholder Rights Law Firm Johnso... [Published Business Wire Professional Services News - Aug 01 2014]
Biota Reports Top-Line Data From Its Phase 2 "I... [Published GlobeNewswire: Acquisitions News - Aug 01 2014]
5 Stocks Under $10 Set to Soar [Published The Street Latest - Jul 11 2014]
Research and Markets: Biota Pharmaceuticals, In... [Published Business Wire Health News - Jun 04 2014]
Biota Announces Restructuring Plan [Published GlobeNewswire: Advertising News - Jun 02 2014]
34% Drop in Biota Pharmaceutical, Inc.'s Stock ... [Published Financial Services - May 12 2014]
Faruqi & Faruqi, LLP Encourages Investors Who S... [Published Financial Services - May 10 2014]
Biota Provides Update on BARDA Contract for Lan... [Published GlobeNewswire: Advertising News - May 08 2014]
Biota Pharmaceuticals Reports Third Quarter 201... [Published GlobeNewswire: Advertising News - May 06 2014]
SHAREHOLDER ALERT: Pomerantz Law Firm Investiga... [Published Financial Services - Apr 29 2014]
Biota Pharmaceuticals, Inc. Announces Upcoming ... [Published GlobeNewswire: Acquisitions News - Apr 29 2014]
Biota reports that laninamivir octanoate is app... [Published Pharmaceutical Business Review - Dec 24 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BIOTA ALERT: Shareholder Rights Law Firm Johnso... [Published Business Wire Professional Services News - Aug 01 2014]
SAN DIEGO--(BUSINESS WIRE)--BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota Pharmaceuticals, Inc ...
Research and Markets: Biota Pharmaceuticals, In... [Published Business Wire Health News - Jun 04 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/965h3w/biota) has announced the addition of the "Biota Pharmaceuticals, Inc. - Product Pipeline Review - 2014" company profile to their offering. This report provides ...
1

Press Releases

sort by: Date | Relevance
Biota Pharmaceuticals to Host Conference Call t... [Published GlobeNewswire: Advertising News - 19 hours ago]
Biota to Present Preclinical Data on RSV Compou... [Published GlobeNewswire: Acquisitions News - Sep 04 2014]
Biota Reports Top-Line Data From Its Phase 2 "I... [Published GlobeNewswire: Acquisitions News - Aug 01 2014]
Biota Announces Restructuring Plan [Published GlobeNewswire: Advertising News - Jun 02 2014]
34% Drop in Biota Pharmaceutical, Inc.'s Stock ... [Published Financial Services - May 12 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.